The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01258205




Registration number
NCT01258205
Ethics application status
Date submitted
9/12/2010
Date registered
10/12/2010
Date last updated
19/05/2017

Titles & IDs
Public title
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease, and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease
Secondary ID [1] 0 0
20090519
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AMG 139

Experimental: Part B - One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease.

Experimental: Part A - Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects.


Treatment: Drugs: AMG 139
Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety & tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139
Timepoint [1] 0 0
36 weeks
Secondary outcome [1] 0 0
Characterization of the pharmacokinetic (PK) parameters (AUCtau, Cmax, tmax) for AMG 139 after multiple IV and SC dose administrations in healthy subjects and subjects with mild to severe CD
Timepoint [1] 0 0
36 weeks

Eligibility
Key inclusion criteria
Part A - Healthy Subjects:

- Healthy male or female of non-reproductive potential subjects between 18 to 45
years-of-age

- Body mass index (BMI) between 18 and 32 kg/m2

- Normal or clinically acceptable physical examination, clinical laboratory values, and
ECG

- Additional inclusion criteria apply

Part B - Crohn's Subjects:

- Male or female subjects with CD between 18 to 55 years-of-age

- Body mass index (BMI) between 18 and 32 kg/m2

- Normal or clinically acceptable physical examination (PE), clinical laboratory values,
and ECG; clinically acceptable PE includes evidence of mild to severe CD

- Diagnosis of ileal or ileo-colonic CD for a minimum of 6 months

- Mild to severe CD defined by a Crohn's Disease Activity Index (CDAI) score equal to or
greater than 180 and equal to or less than 450

- Elevated fecal calprotectin and CRP

- Additional inclusion criteria apply
Minimum age
18 Years
Maximum age
55 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Parts A - Healthy Subjects:

- History or evidence of a clinically significant disorder (including psychiatric),
condition or disease that would pose a risk to subject safety or interfere with the
study evaluation, procedures or completion;

- Recent or on-going infection(s)

- Underlying condition(s) that predisposes the subject to infections

- History of malignancy of any type

- Additional exclusion criteria apply

Part B only - Crohn's Subjects:

- History or evidence of a clinically significant disorder (including psychiatric),
condition or disease that would pose a risk to subject safety or interfere with the
study evaluation, procedures or completion;

- Recent or on-going infection(s)

- Underlying condition(s) that predisposes the subject to infections

- History of malignancy of any type

- Additional exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 0 0
QPharm Pty Limited - Herston
Recruitment hospital [2] 0 0
Clinical Medical and Analytical eXellence CMAX - Adelaide
Recruitment hospital [3] 0 0
Centre for Clinical Studies (Alfred) - Prahran
Recruitment postcode(s) [1] 0 0
4029 - Herston
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3181 - Prahran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New Jersey
Country [2] 0 0
United States of America
State/province [2] 0 0
New York
Country [3] 0 0
United States of America
State/province [3] 0 0
Oklahoma
Country [4] 0 0
United States of America
State/province [4] 0 0
Virginia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Allergan
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety and tolerability of AMG 139 following
multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in
subjects with mild to severe Crohn's disease (CD).
Trial website
https://clinicaltrials.gov/show/NCT01258205
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Carl Gommoll, MS
Address 0 0
Allergan
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications